vs
SAUL CENTERS, INC.（BFS）与IOVANCE BIOTHERAPEUTICS, INC.（IOVA）财务数据对比。点击上方公司名可切换其他公司
IOVANCE BIOTHERAPEUTICS, INC.的季度营收约是SAUL CENTERS, INC.的1.2倍（$86.8M vs $75.1M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs 10.6%），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs 6.2%）
Saul Centers, Inc.是一家总部位于美国的自主运营房地产投资信托，主要持有、运营及开发优质购物中心、混合用途物业与多户住宅资产，核心资产组合集中在华盛顿大都会区及美国其他精选高增长区域市场。
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
BFS vs IOVA — 直观对比
营收规模更大
IOVA
是对方的1.2倍
$75.1M
营收增速更快
IOVA
高出7.1%
10.6%
两年增速更快
IOVA
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $86.8M |
| 净利润 | $6.5M | — |
| 毛利率 | — | 67.4% |
| 营业利润率 | 65.4% | -84.7% |
| 净利率 | 8.7% | — |
| 营收同比 | 10.6% | 17.7% |
| 净利润同比 | -19.6% | — |
| 每股收益（稀释后） | $0.15 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFSIOVA
| Q4 25 | $75.1M | $86.8M | ||
| Q3 25 | $72.0M | $67.5M | ||
| Q2 25 | $70.8M | $60.0M | ||
| Q1 25 | $71.9M | $49.3M | ||
| Q4 24 | $67.9M | $73.7M | ||
| Q3 24 | $67.3M | $58.6M | ||
| Q2 24 | $66.9M | $31.1M | ||
| Q1 24 | $66.7M | $715.0K |
净利润BFSIOVA
| Q4 25 | $6.5M | — | ||
| Q3 25 | $10.5M | $-91.3M | ||
| Q2 25 | $10.7M | $-111.7M | ||
| Q1 25 | $9.8M | $-116.2M | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $14.5M | $-83.5M | ||
| Q2 24 | $14.4M | $-97.1M | ||
| Q1 24 | $13.6M | $-113.0M |
毛利率BFSIOVA
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | 73.6% | 46.2% | ||
| Q2 24 | 74.2% | -0.8% | ||
| Q1 24 | 72.8% | — |
营业利润率BFSIOVA
| Q4 25 | 65.4% | -84.7% | ||
| Q3 25 | 69.1% | -140.7% | ||
| Q2 25 | 68.7% | -189.8% | ||
| Q1 25 | 66.5% | -245.8% | ||
| Q4 24 | 82.9% | -117.5% | ||
| Q3 24 | 72.8% | -152.1% | ||
| Q2 24 | 75.0% | -327.6% | ||
| Q1 24 | 72.4% | -16464.6% |
净利率BFSIOVA
| Q4 25 | 8.7% | — | ||
| Q3 25 | 14.6% | -135.3% | ||
| Q2 25 | 15.1% | -186.2% | ||
| Q1 25 | 13.6% | -235.5% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 21.5% | -142.7% | ||
| Q2 24 | 21.6% | -312.2% | ||
| Q1 24 | 20.4% | -15800.8% |
每股收益（稀释后）BFSIOVA
| Q4 25 | $0.15 | — | ||
| Q3 25 | $0.32 | — | ||
| Q2 25 | $0.33 | $-0.33 | ||
| Q1 25 | $0.29 | $-0.36 | ||
| Q4 24 | $0.22 | $-0.24 | ||
| Q3 24 | $0.48 | $-0.28 | ||
| Q2 24 | $0.48 | $-0.34 | ||
| Q1 24 | $0.45 | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.7M | $297.0M |
| 总债务越低越好 | $468.4M | — |
| 股东权益账面价值 | $307.8M | $698.6M |
| 总资产 | $2.2B | $913.2M |
| 负债/权益比越低杠杆越低 | 1.52× | — |
8季度趋势，按日历期对齐
现金及短期投资BFSIOVA
| Q4 25 | $8.7M | $297.0M | ||
| Q3 25 | $11.8M | $300.8M | ||
| Q2 25 | $5.3M | $301.2M | ||
| Q1 25 | $6.5M | $359.7M | ||
| Q4 24 | $10.3M | $323.8M | ||
| Q3 24 | $7.2M | $397.5M | ||
| Q2 24 | $6.9M | $412.5M | ||
| Q1 24 | $7.1M | $356.2M |
总债务BFSIOVA
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益BFSIOVA
| Q4 25 | $307.8M | $698.6M | ||
| Q3 25 | $316.6M | $702.3M | ||
| Q2 25 | $322.4M | $698.5M | ||
| Q1 25 | $328.4M | $767.9M | ||
| Q4 24 | $335.8M | $710.4M | ||
| Q3 24 | $341.8M | $773.5M | ||
| Q2 24 | $345.7M | $768.5M | ||
| Q1 24 | $347.1M | $680.0M |
总资产BFSIOVA
| Q4 25 | $2.2B | $913.2M | ||
| Q3 25 | $2.2B | $904.9M | ||
| Q2 25 | $2.1B | $907.4M | ||
| Q1 25 | $2.1B | $966.7M | ||
| Q4 24 | $2.1B | $910.4M | ||
| Q3 24 | $2.1B | $991.1M | ||
| Q2 24 | $2.1B | $964.3M | ||
| Q1 24 | $2.0B | $869.8M |
负债/权益比BFSIOVA
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.8M | $-52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-61.9M |
| 自由现金流率自由现金流/营收 | — | -71.3% |
| 资本支出强度资本支出/营收 | — | 10.7% |
| 现金转化率经营现金流/净利润 | 15.35× | — |
| 过去12个月自由现金流最近4个季度 | — | $-336.2M |
8季度趋势，按日历期对齐
经营现金流BFSIOVA
| Q4 25 | $99.8M | $-52.6M | ||
| Q3 25 | $20.6M | $-78.7M | ||
| Q2 25 | $26.6M | $-67.4M | ||
| Q1 25 | $30.4M | $-103.7M | ||
| Q4 24 | $121.2M | $-73.3M | ||
| Q3 24 | $26.5M | $-59.0M | ||
| Q2 24 | $32.1M | $-98.4M | ||
| Q1 24 | $33.8M | $-122.3M |
自由现金流BFSIOVA
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | $-28.3M | $-61.3M | ||
| Q2 24 | $-12.5M | $-98.9M | ||
| Q1 24 | $-11.7M | $-126.5M |
自由现金流率BFSIOVA
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | -42.1% | -104.6% | ||
| Q2 24 | -18.7% | -317.9% | ||
| Q1 24 | -17.6% | -17685.3% |
资本支出强度BFSIOVA
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 81.5% | 3.9% | ||
| Q2 24 | 66.7% | 1.4% | ||
| Q1 24 | 68.3% | 583.4% |
现金转化率BFSIOVA
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BFS
暂无分部数据
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
